BioResponse, LLC

BioResponse LLC (BR) focuses on the research, development, and manufacturing of patented diindolylmethane formulations. The company’s mission for over 25 years has been its commitment to research supporting future therapeutic uses of diindolylmethane. BR has developed patented small molecule drug product candidates with novel formulation technology. Both oral and IV formulations provide neuroprotection in treating acute Central Nervous System injury. Boulder BioScience (BBS), LLC, the sister company of BR, is focused on neuroprotection. BBS’s mission is to advance breakthrough science for acute-care indications to fill critical, unmet needs in Military Medicine. The drug candidates provide promising new treatments for traumatic brain injury (TBI), Concussion, Blast Injury, and Acute Ischemic Stroke. Translation of candidates to EMT administered, post-injury use will provide immediate protection of the Blood Brain Barrier, prevent Cerebral Edema, minimize Brain Contusions, and contribute to neurocognitive recovery.